昭衍新藥 (6127.HK)

9.430 -0.150 (-1.57%) 市場開市。 截至 02:51PM HKT。

昭衍新藥

A5 Rongjing East Street
Beijing Eco-Techno Development Area
Beijing 100176
China
86 10 6786 9582
https://www.joinn-lab.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 2,510

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Yuxia Feng M.D.	Founder & Chairman	無	無	1964
Mr. Dapeng Gao	GM, Secretary to the Board, Joint Company Secretary & Executive Director	無	無	1982
Dr. Conglin Zuo M.D.	Co-Founder & Vice Chairman	無	無	1964
Ms. Aishui Yu	Chief Financial Officer	無	無	1976
Mr. Jingliang Gu	Vice GM & Head of Sales Department	無	無	1980
Dr. Yunxia Sun DCBT, M.D.	Vice GM & Executive Director	無	無	1968
Dr. Dalin Yao	Senior Vice GM, Chief Scientific Officer & Executive Director	無	無	1949
Ms. Ka Lun Cheung	Joint Company Secretary	無	無	1989

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics studies, and pharmacology and efficacy studies. The Clinical Trial and Related Services segment provides clinical CRO services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment designs, produces, breeds, and sells research models, non-human primates, and rodents. The company also offers cell-based assay (CBA) services. Joinn Laboratories(China)Co.,Ltd. was founded in 1995 and is headquartered in Beijing, China.

公司管治

截至 無 止，昭衍新藥 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。